Articles about Biotechnology – Page 3 of 4

Fred Hutch president says they’ve got cancer ‘running scared,’ predicts cure in 10 years

There’s a tsunami on the horizon, and it has cancer “running scared.” Those were the words from Fred Hutchinson Cancer… Read More

Juno CEO Hans Bishop: The $1 billion Celgene deal could be the ‘most productive’ collaboration in biotech

Juno Therapeutics is no stranger to huge financing deals. The Seattle biotech company, which emerged on the scene just two… Read More

Juno stock skyrockets after Celgene invests $1 billion to change the way cancer is treated

Shares of Seattle-based biotech startup Juno Therapeutics spiked more than 60 percent in after-hours trading on Monday after the company announced… Read More

Shares of Juno Therapeutics jump after Seattle biotech buys X-BODY Inc.

Shares of Juno Therapeutics jumped more than six percent on Tuesday after the Seattle biotechnology company announced its acquisition of… Read More

Nonprofit Seattle BioMed changes name to Center for Infectious Disease Research

The largest independent nonprofit in the U.S. focused solely on infectious disease research is changing its name to better align… Read More

Juno Therapeutics inks lease for new building in Seattle’s bustling South Lake Union neighborhood

Fast-growing Juno Therapeutics — fresh off its IPO from last December — is expanding its presence in its hometown of… Read More

Bankrupt cancer drug maker Dendreon selling to Valeant for $400 million

Dendreon, the once-promising Seattle biotechnology company that developed treatments for prostate cancer, will be sold to Quebec-based Valeant Pharmaceuticals International Inc.… Read More

Fast-growing cancer research company Juno Therapeutics to open Seattle area manufacturing facility

Juno Therapeutics, the fast-growing Seattle biotechnology company, today announced that it plans to open a new manufacturing facility in Bothell… Read More

Adaptive Biotechnologies buys Sequenta to expedite cancer, infectious disease treatments

Adaptive Biotechnologies, a Seattle company that’s working on sequencing to profile T-cell and B-cell receptors, today announced that it is acquiring… Read More

Cerevast raises $10M for ‘ClotBuster’ ultrasonic headframe device, a new therapy for stroke patients

Cerevast Therapeutics, a 5-year-old Redmond company that’s developing a novel approach for treating stroke patients with ultrasound, has raised $10 million… Read More

Juno Therapeutics prices IPO at $24, shares soar in debut

Juno Therapeutics, a heavily-funded cancer research company that was formed just 16 months ago, priced its initial public offering Thursday… Read More

Juno Therapeutics sets IPO range at $15 to $18 per share, looks to raise $166M

Fast-moving Juno Therapeutics is moving closer to becoming a publicly-traded company. The Seattle biotechnology company today updated is IPO filing… Read More

Fred Hutch names prominent genetics expert president, 5th in cancer research center’s 40-year history

Seattle’s Fred Hutchinson Cancer Research Center has tapped D. Gary Gilliland, an expert in cancer genetics and former vice president of precision medicine… Read More

Tech Moves: Shauna Causey joins EveryMove; Ex-Dropcam exec named to SNUPI board; and more

—Startup vet Shauna Causey — a former marketing executive at UP Global and Decide.com — has landed a new gig… Read More

Drug maker Novo Nordisk confirms new obesity R&D center in Seattle

Danish drug maker Novo Nordisk announced plans today to open a new obesity research unit in Seattle, a move that… Read More

Cancer research startup VentiRx lands $50M

Seattle’s biotech industry has been on an up-and-down roller coaster ride over the past 12 months, with layoffs and R&D… Read More

Big news for biotech: Novo Nordisk considering Seattle for new obesity R&D center

Seattle has been struck with some tough setbacks in the biotech community in the past few months, including the recent… Read More

Novo Nordisk cutting workforce, focusing efforts on diabetes treatments

Here’s another dose of bad news for Seattle’s biotech industry. Novo Nordisk this week announced plans to discontinue R&D efforts… Read More

Amazon’s new waterfront home? Five ideas for Amgen’s beautiful Seattle campus

News that Amgen plans to shutter its 40-acre campus along Elliott Bay marks yet another setback for Seattle’s biotech industry,… Read More

Biotechnology investor Accelerator Corp. lands $51 million, expands in New York City

Accelerator Corp, the Seattle biotechnology investment fund started in Seattle 11 years ago, has raised $51.1 million in capital as… Read More

Cancer research company Immune Design sets IPO range at $12 to $14 per share

Seattle biotechnology company Immune Design, which is working on novel technologies that activate the body’s immune system to fight cancer,… Read More

Cancer research startup Immune Design files for $60 million IPO

Immune Design Corp., a Seattle biotechnology company developing technologies to activate the body’s immune system to fight cancer, has filed… Read More

More funding for cancer research in Seattle: Adaptive Biotechnologies raises $105M

Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same… Read More

Seattle BioMed lands $9.8M grant to study HIV vaccine

Seattle BioMed has received a $9.8 million grant from National Institute of Allergy and Infectious Diseases to fund the initial phases… Read More

NanoString files for $55M stock offering, expects 37% revenue growth for 2013

NanoString Technologies, a provider of life science tools for research and molecular diagnostic products, has filed to raise $55 million… Read More

With $120M in its pocket, Juno Therapeutics aims to wipe out cancer by rewiring the immune system

One big problem with existing cancer therapies available today like chemotherapy and radiation is the collateral damage. While some medicine… Read More

Cancer research startup Juno Therapeutics raises $120M in massive series A financing

In one of the largest series A venture capital deals this year in the biotechnology sector, Seattle-based Juno Therapeutics has… Read More

Tumor paint startup Blaze Bioscience raises $9M to help surgeons pinpoint cancer cells

Blaze Bioscience has raised $9 million in fresh funding from individual investors, money that the Seattle spinoff of the Fred… Read More

Money-losing Dendreon to cut 150 employees in bid to become ‘nimble’ biotech company

Once a rising star in Seattle’s biotechnology community, Dendreon Corp. announced Tuesday that it is reducing its staff by 15… Read More

Cancer research startup Immune Design pulls in $32.5 million, plans to raise more

Immune Design has reeled in $32.5 million in venture capital financing, with plans to raise up to $16.5 million more… Read More